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Abstract. 
 
TGF-
 
b
 
 inhibits adipocyte differentiation, yet 
is expressed by adipocytes. The function of TGF-
 
b
 
 in 
adipogenesis, and its mechanism of action, is unknown. 
To address the role of TGF-
 
b
 
 signaling in adipocyte dif-
ferentiation, we characterized the expression of the 
TGF-
 
b
 
 receptors, and the Smads which transmit or in-
hibit TGF-
 
b
 
 signals, during adipogenesis in 3T3-F442A 
cells. We found that the cell-surface availability of
TGF-
 
b
 
 receptors strongly decreased as adipogenesis 
proceeds. Whereas mRNA levels for Smads 2, 3, and 4 
were unchanged during differentiation, mRNA levels 
for Smads 6 and 7, which are known to inhibit TGF-
 
b
 
 
responses, decreased severely. Dominant negative in-
terference with TGF-
 
b
 
 receptor signaling, by stably ex-
pressing a truncated type II TGF-
 
b
 
 receptor, enhanced 
differentiation and decreased growth. Stable overex-
pression of Smad2 or Smad3 inhibited differentiation 
and dominant negative inhibition of Smad3 function, 
but not Smad2 function, enhanced adipogenesis. In-
creased Smad6 and Smad7 levels blocked differentia-
tion and enhanced TGF-
 
b
 
–induced responses. The in-
hibitory effect of Smad7 on adipocyte differentiation 
and its cooperation with TGF-
 
b
 
 was associated with the 
C-domain of Smad7. Our results indicate that endoge-
nous TGF-
 
b
 
 signaling regulates the rate of adipogene-
sis, and that Smad2 and Smad3 have distinct functions 
in this endogenous control of differentiation. Smad6 
and Smad7 act as negative regulators of adipogenesis 
and, even though known to inhibit TGF-
 
b
 
 responses, 
enhance the effects of TGF-
 
b
 
 on these cells.
Key words: inhibitory Smads • PPAR
 
g
 
 • C/EBP • 
3T3-F442A • retroviral vectors
 
Introduction
 
TGF-
 
b
 
 regulates the differentiation program of a variety
of cell types (for review see Derynck and Choy, 1998), in-
cluding mesenchymal cells. For example, myogenesis is in-
hibited or stimulated by TGF-
 
b 
 
depending on the cell type
and the culture conditions. The addition of TGF-
 
b
 
 gener-
ally inhibits myoblast differentiation (Massagué et al.,
1986; Olson et al., 1986), but stimulates differentiation of
embryonic myoblasts (Slager et al., 1993), whereas inhibi-
tion of type II TGF-
 
b
 
 receptor signaling in C2C12 myo-
blasts blocks myogenic differentiation (Filvaroff et al.,
1994). These data suggest that TGF-
 
b
 
 signaling is required
and provides competence for the early stages of myogenic
differentiation, but inhibits later stages in the differentia-
tion process. Such a model may also explain the many
findings on stimulatory and inhibitory effects of TGF-
 
b
 
 on
chondrocyte and osteoblast differentiation, which likewise
depend on culture conditions and the differentiation state
of the cells (Kulyk et al., 1989; Ballock et al., 1993; Cen-
trella et al., 1994). These dynamic responses of muscle and
bone cells to TGF-
 
b
 
 may relate to changes in receptor lev-
els and ratios during differentiation (Hu and Olson, 1990;
Centrella et al., 1995), and may highlight the complexity of
differentiation responses of mesenchymal cells to TGF-
 
b
 
.
While the effects of TGF-
 
b
 
 signaling on muscle, bone,
and cartilage cell differentiation are well studied, little is
known about how TGF-
 
b
 
 regulates adipocyte differentia-
tion. Furthermore, the mechanism by which TGF-
 
b
 
 stimu-
lates proliferation of mesenchymal cells (Sporn et al.,
1986), including preadipocytes (Jeoung et al., 1995), is also
poorly understood. It is known that TGF-
 
b
 
 inhibits adi-
pose differentiation of preadipocyte cell lines and primary
cultures (Ignotz and Massagué, 1985; Sparks and Scott,
1986; Torti et al., 1989; Petruschke et al., 1994). In some
preadipocyte cell lines, TGF-
 
b
 
 must be administered be-
fore, or concomitant with, the induction of differentiation,
after which the cells are refractory to TGF-
 
b
 
 and do not
revert to the undifferentiated state (Ignotz and Massagué,
1985; Sparks et al., 1992). However, TGF-
 
b
 
 treatment can,
in other cells, reverse the adipocyte phenotype (Torti et
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al., 1989) or reduce expression of differentiation markers
in fully differentiated adipocytes (Petruschke et al., 1994).
TGF-
 
b
 
 also blocks adipogenesis in vivo. Transgenic over-
expression of TGF-
 
b
 
1 in adipose tissue severely reduces
both white and brown adipose tissue masses, and results in
the failure of adipocytes to differentiate (Clouthier et al.,
1997). In spite of its ability to inhibit adipocyte differentia-
tion, TGF-
 
b
 
 is expressed in cultured adipocytes (Sparks et
al., 1993; Bortell et al., 1994), and adipose tissue (Samad et
al., 1997). The relative increase of TGF-
 
b
 
 levels in obese
adipose tissue may result from increased expression of tu-
mor necrosis factor 
 
a
 
 (Samad et al., 1999), another cyto-
kine that, like TGF-
 
b
 
, inhibits adipocyte differentiation in
vitro (Torti et al., 1985).
Collectively, these observations suggest a role for en-
dogenous TGF-
 
b
 
 in the development and function of adi-
pose tissue. However, very little is known about the signal-
ing mechanisms that lead to the differentiation responses
to TGF-
 
b
 
. TGF-
 
b
 
 family factors bind to a heteromeric
cell-surface complex of two type II and two type I recep-
tors (for reviews see Derynck and Feng, 1997; Heldin et
al., 1997; Massagué, 1998). Both receptor types are trans-
membrane serine/threonine kinases, and ligand binding in-
duces phosphorylation and activation of the type I recep-
tors by the type II receptor kinases. The Smad proteins act
as effectors of the signaling by activated TGF-
 
b
 
 receptors.
Upon COOH-terminal phosphorylation by type I TGF-
 
b
 
receptors, Smad2 and/or Smad3 heteromerize with the
common partner Smad4 and are translocated into the nu-
cleus (for reviews see Heldin et al., 1997; Derynck et al.,
1998; Massagué, 1998; Whitman, 1998). Once there, they
act as transcriptional coactivators or corepressors, through
interactions with other transcription factors such as FAST-
1/2 (Chen et al., 1997; Liu et al., 1999) c-Jun/c-Fos (Zhang
et al., 1998), coactivators such as CBP (Feng et al., 1998;
Janknecht et al., 1998; Topper et al., 1998), or corepressors
such as TGIF (Wotton et al., 1999) or c-Ski (Stroschein et
al., 1999; Sun et al., 1999). The TGF-
 
b
 
 response can also
be regulated by Smad6 and Smad7, which inhibit the TGF-
 
b
 
–induced activation of Smad2 and Smad3 (Hayashi et al.,
1997; Imamura et al., 1997). The complexity of the TGF-
 
b
 
responses and their dependence on the physiological con-
text and cell type, may relate to the relative levels of the
different Smads, and their cooperativity with a variety of
transcription factors, which themselves may be regulated
by different signaling pathways (Zhang and Derynck,
1999).
The expression and function of these components of the
TGF-
 
b
 
 signaling pathway during adipocyte differentiation,
and the role of endogenous TGF-
 
b
 
 expression and TGF-
 
b
 
responsiveness in the regulation of adipocyte differentia-
tion, are unknown. It is known that the block in differenti-
ation induced by TGF-
 
b
 
 is accompanied by decreased
mRNA levels for C/EBP
 
a
 
 and PPAR
 
g
 
 (Stephens et al.,
1993; Xing et al., 1997), transcription factors which are
critical for adipogenesis (Grégoire et al., 1998). However,
the mechanism of this suppression is unknown, and, since
these transcription factors are subject to positive autoreg-
ulation and positive cross-regulation (Tontonoz et al.,
1994; Clarke et al., 1997; Tang et al., 1999), it is unclear
whether this repression is a cause or an effect of blocked
differentiation. To begin to elucidate the mechanism of
TGF-
 
b
 
 signaling in adipocyte differentiation, we have now
characterized the expression of the TGF-
 
b
 
 receptors and
Smads during differentiation of the murine preadipocyte
cell line, 3T3-F442A. To determine the role of these sig-
naling mediators, we altered TGF-
 
b
 
 receptor signaling by
stably overexpressing a dominant negative mutant of the
type II TGF-
 
b
 
 receptor, thereby inhibiting the TGF-
 
b
 
 re-
sponsiveness, or by overexpressing wild-type or dominant
negative mutants of Smad2 or Smad3, wild-type Smad6 or
Smad7, or Smad7 mutants. The consequences of these
changes in signaling on adipogenesis strongly suggest that
endogenous TGF-
 
b
 
 responsiveness regulates adipocyte
differentiation, and that Smad2 and Smad3, and the inhib-
itory Smad6 and 7, have distinct roles in the adipogenic
differentiation process.
 
Materials and Methods
 
Construction of Expression Plasmids
 
Expression plasmids for the cytoplasmically truncated, dominant negative
version of the type II TGF-
 
b
 
 receptor (dnT
 
b
 
RII;
 
1
 
 Chen et al., 1993) or for
Smad2 or Smad3 (Zhang et al., 1998) were described previously. The cod-
ing sequence for the Smad2
 
D
 
SSMS mutant was generated by removing
the COOH-terminal sequence of Smad2 at the BamHI site, which is lo-
cated 33 bp upstream of the stop codon, and replacing it with annealed oli-
gonucleotides encoding the identical DNA sequence but lacking the last
four codons. The cDNA for Smad3
 
D
 
SSVS was created by PCR amplifica-
tion of the human Smad3 sequence without the last four codons, and was
obtained from Y. Zhang (University of California, San Francisco, San
Francisco, CA). The cDNAs for mouse Smad6 and mouse Smad7 were
obtained from K. Miyazono (The Cancer Institute of Japanese Founda-
tion for Cancer Research, Tokyo, Japan) and P. ten Dijke (Ludwig Insti-
tute for Cancer Research, Uppsala, Sweden), respectively. Mutant ver-
sions of mouse Smad7 containing a 19–amino acid deletion at the COOH
terminus (Smad7
 
D
 
C) or consisting only of the C-domain, amino acids
204–426 (Smad7C), were obtained from P. ten Dijke.
Retroviral vectors were used to establish stable cell populations over-
expressing components of the TGF-
 
b
 
 signaling pathway. The coding se-
quence for the dominant negative type II TGF-
 
b
 
 receptor, along with its
COOH-terminal Flag tag, was subcloned into the HpaI site of the LNCX
vector, which allows selection in the neomycin derivative G418 (Miller
and Rosman, 1989). Smad2 and Smad3 and their dominant negative mu-
tants were expressed from a new derivative of LNCX, which we named
LPCX, and allows for selection in puromycin instead of G418. This plas-
mid was made by replacing the 
 
neo
 
r
 
 gene of LNCX with the puromycin re-
sistance gene from pBabepuro (Morgenstern and Land, 1990). The coding
regions for NH
 
2
 
 terminally Flag-tagged Smad2, Smad2
 
D
 
SSMS, Smad3,
and Smad3
 
D
 
SSVS were inserted into the HpaI site of LPCX. The coding
regions for the NH
 
2
 
 terminally Flag-tagged Smad6, Smad7
 
D
 
C, and
Smad7C were cloned into the BamHI-XhoI sites of pBabepuro3, whereas
the coding region of Smad7 were cloned into the BamHI/blunt-ended
EcoRI site of pBabepuro3.
 
Cell Culture and Generation of Stable Cell Lines
 
The preadipocyte cell line 3T3-F442A (Green and Kehinde, 1976) was ob-
tained from H. Green (Harvard Medical School, Boston, MA). The cells
were grown and differentiated as described (Dobson et al., 1987), except
that incubators were set at 5% rather than 10% CO
 
2
 
. To study differentia-
tion in the presence of TGF-
 
b
 
, TGF-
 
b
 
 was added to the medium 2 d be-
fore confluence, and again at every medium change (three times per
week). The ecotropic retroviral packaging cell line Phoenix E was ob-
tained from G. Nolan (Stanford University, Stanford, CA), and main-
tained in DME with 3 g/liter glucose (Cellgro), 10% FBS (Hyclone Labo-
ratories Inc.), 10 U/ml penicillin, and 10 
 
m
 
g/ml streptomycin.
To generate retroviruses, Phoenix E cells were plated at 2.7 
 
3
 
 10
 
6
 
 cells/
60-mm tissue culture dish 24 h before transfection. Transfection was done
 
1
 
Abbreviations used in this paper:
 
 dnT
 
b
 
RI and II, type I and II TGF-
 
b
 
 re-
ceptor, respectively.
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using the calcium phosphate method (Gorman et al., 1983), using 10 
 
m
 
g
DNA per plate. 48 h after transfection, the conditioned medium contain-
ing recombinant retroviruses was collected and filtered through 0.45-
 
m
 
m
sterilization filters. 1–1.3 ml of these supernatants were applied immedi-
ately to 3T3-F442A cells, which had been plated 18 h before infection at a
density of 5.1 
 
3
 
 10
 
4
 
 cells/well of 6-well dishes. Polybrene (Sigma Chemical
Co.) was added to a final concentration of 8 
 
m
 
g/ml, and the supernatants
were incubated with the cells for 3–5 h. Alternatively, cells overlaid with
viral supernatants plus polybrene were centrifuged for 45 min at room
temperature at 1,800 rpm in a Beckman GPR centrifuge. The medium was
aspirated and replaced with fresh viral supernatant, and the procedure
was repeated. After infection, the cells were placed in fresh growth me-
dium and cultured as usual. Selection with 1 mg/ml G418 (Life Technolo-
gies, Inc.) or 2 
 
m
 
g/ml puromycin (Calbiochem) was initiated 48 h after in-
fection.
 
Assay of Cell Growth Rates
 
Cells were trypsinized, resuspended in growth medium without selective
antibiotic, and 2 
 
3 
 
10
 
4
 
 cells were plated per well of 24-well dishes. The
cells were washed twice with PBS on the following day, and then overlaid
with DME containing 0.5% BSA (Sigma Chemical Co.) either without or
with the indicated concentrations of TGF-
 
b
 
. The next day, [
 
3
 
H]thymidine
(2 Ci/mmol; NEN) was added to the medium at a concentration of 4 
 
m
 
Ci/
ml. Uptake of the label proceeded for 4–5 h. Cells were washed twice with
PBS, fixed for 20 min with 10% TCA, washed twice with water, and solu-
bilized for 20 min in 1 N NaOH. An equal volume of 1 N HCl was added,
and the resulting lysate was subjected to liquid scintillation counting.
 
Analysis of Lipid Accumulation, RNA, and Protein
 
Neutral lipid accumulation was visualized by washing cell monolayers
once with PBS, fixing for 15 min with buffered formalin, and staining them
for 1 h in a freshly made solution containing four parts water mixed with
six parts 0.5% Oil Red O (Sigma Chemical Co.) in isopropanol. Excess
stain was removed, and the cells were washed several times with water.
RNA was isolated using the SV RNA isolation kit (Promega). 10 
 
m
 
g to-
tal RNA was denatured and electrophoresed in 1% formaldehyde gels,
blotted to Biotrans nylon membranes (ICN), and hybridized to 
 
32
 
P-
labeled cDNA probes, as described previously (Ausubel et al., 1994).
DNA probes were labeled to a specific activity of at least 10
 
9
 
 dpm/
 
m
 
g with
[
 
32
 
P]
 
a
 
-dCTP (6,000 Ci/mmol; NEN) by the random priming method
(Feinberg and Vogelstein, 1983). The cDNAs for C/EBP
 
a
 
, PPAR
 
g
 
2,
ADD-1/SREBP1, aP2 and adipsin were obtained from B. Spiegelman
(Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA).
The cDNAs for C/EBPs 
 
b
 
 and 
 
d
 
 were provided by S. McKnight (Univer-
sity of Texas, Southwestern Medical Center, Dallas, TX).
 
125
 
I-labeled TGF-
 
b
 
1 was purchased from NEN. Cross-linking to
[
 
125
 
I]TGF-
 
b
 
 was performed as described (Gazit et al., 1993). Mild acetic
acid washes and suramin (Calbiochem) treatment of cell monolayers, to
remove any potentially endogenously produced bound TGF-
 
b
 
, were done
as previously described (Beauchamp et al., 1992; Wade et al., 1992). Cell
lysates were prepared as previously described (Chen and Derynck, 1994).
For analysis of endogenous receptors, equal amounts of protein (400 
 
m
 
g of
each sample) were loaded in each lane. For analysis of receptor expres-
sion in stable dnT
 
b
 
RII expressing and control cells, 20% of the total ly-
sates was reserved for direct loading on the gel, while the remaining 80%
was subjected to immunoprecipitation with anti-FlagM2 IgG (Sigma
Chemical Co.) as described previously (Chen and Derynck, 1994). For
analysis of Smad expression in the Smad-expressing stable cell lines, Flag-
tagged proteins were detected in whole cell lysates by immunoprecipita-
tion using anti-FlagM2–conjugated beads (Sigma Chemical Co.), followed
by SDS-PAGE and Western blotting, using the enhanced chemilumines-
cence method (Amersham Pharmacia Biotech) with anti-FlagM2 IgG as
the primary antibody.
 
Results
 
Cell-Surface TGF-
 
b
 
 Receptors Decrease
during Adipogenesis
 
3T3-F442A cells spontaneously undergo adipose differen-
tiation, after reaching confluence in culture in the pres-
ence of FBS and insulin (Green and Kehinde, 1976). Typi-
cally, 5–10% of the cells have accumulated lipid droplets
at 1 d after confluence, 30–40% by 3 d, and by 8 d after
confluence, 
 
z
 
90% of the cells have become adipocytes.
To examine the role of endogenous TGF-
 
b
 
 signaling in ad-
ipogenesis, we first compared the mRNA expression levels
for the type II and the type I TGF-
 
b
 
 receptor (T
 
b
 
RII and
T
 
b
 
RI, respectively) in confluent preadipocytes versus dif-
ferentiated adipocytes (Fig. 1 A). Both the preadipocytes
and the adipocytes expressed T
 
b
 
RII and T
 
b
 
RI mRNA.
Whereas the T
 
bRII mRNA level was similar in preadipo-
cytes and adipocytes, TbRI mRNA levels increased in dif-
ferentiated cells.
The expression of TbRII and TbRI at the cell surface
was assessed by cross-linking 125I-labeled TGF-b to the
cells (Fig. 1 B). While preadipocytes expressed type III
TGF-b receptor (bglycan), TbRII, and TbRI at the cell
surface, the availability of these receptors strongly de-
creased during differentiation. These decreased levels
were not a consequence of receptor occupation by unla-
beled TGF-b preventing [125I]TGF-b binding since re-
moval of endogenous ligand by suramin or acid washes did
not enhance receptor binding of [125I]TGF-b (data not
shown). The total expression levels of the receptors could
not be determined because of the low expression levels
and limited quality of the available antibodies (data not
shown). The strong decrease in cell-surface availability of
the receptors during adipose differentiation, in contrast to
the mRNA levels for TbRII and TbRI, indicates that the
cells posttranscriptionally downregulate TGF-b binding as
they differentiate.
Regulation of Smad Expression during
Adipocyte Differentiation
Smads act as intracellular effectors of TGF-b signaling.
Smad2 and Smad3 are activators of TGF-b responses, and
form heteromeric complexes with the common mediator
Smad4. In contrast, Smad6 and Smad7 block TGF-b re-
sponses. We assessed the mRNA expression of these
Smads at different stages of adipose differentiation, both
Figure 1. TGF-b receptor expression during adipocyte differenti-
ation of 3T3-F442A cells. (A) Northern analysis of TbRII and
TbRI mRNA expression on 2 mg of poly(A)1 RNA from preadi-
pocytes (pread) or 8-d after confluent adipocytes (ad). Levels of
C/EBPb mRNA are shown as a loading control. (B) Cell-surface
availability of TGF-b receptors, as assessed by chemical cross-
linking to [125I]TGF-b, decreases during differentiation. TGF-b
binding was assessed in confluent preadipocytes (pread) and at 1,
3, and 10 d after confluence. The approximate positions of type
III (RIII), type II (RII), and type I (RI) receptors are indicated.
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in TGF-b–treated and untreated cells (Fig. 2). In these ex-
periments, the TGF-b–treated cells failed to differentiate,
as judged from the absence of lipid accumulation, al-
though analysis of PPARg mRNA expression indicated
that differentiation was not entirely blocked, but strongly
decreased and delayed. Thus, PPARg expression in-
creased with time in TGF-b–treated cells, but never
achieved the expression level seen in untreated cells (Fig.
2). All five Smads were expressed at all stages of differen-
tiation of these cells. The Smad2 or Smad4 mRNA levels
were unaffected by the differentiation stage or by TGF-b,
whereas Smad3 mRNA levels did not significantly change
during differentiation, but were decreased by TGF-b. This
TGF-b–induced repression decreased with the progres-
sion of adipose differentiation. Both Smad6 and Smad7
mRNAs decreased during differentiation, with Smad7
mRNA levels decreasing more abruptly than Smad6. In
addition, TGF-b increased Smad7 expression, but did not
have a significant effect on Smad6 mRNA levels. We were
unable to clearly detect endogenous Smad proteins, most
likely because of poor antibody quality and/or low protein
abundance (data not shown). Collectively, our data show
that all TGF-b Smads are expressed in 3T3-F442A cells,
and that expression of the inhibitory Smads decreases dur-
ing adipogenesis.
Decreased TGF-b Receptor Signaling Results in 
Accelerated Adipogenesis
Since the levels of cell-surface TGF-b receptors and inhib-
itory Smads decreased during adipocyte differentiation,
we determined the role of endogenous TGF-b signaling
and Smads in the growth and differentiation of these cells.
We created cell lines, via retroviral transduction, which
stably expressed individual components of the TGF-b sig-
naling system. First, we attempted to generate cells that
would stably overexpress wild-type TbRII, to counteract
the differentiation-linked suppression of cell-surface TGF-b
receptors. However, the virally expressed TbRII levels,
while not decreased during differentiation as the endoge-
nous receptors (data not shown), were too low to signifi-
cantly change the overall receptor level or profile dur-
ing differentiation. In contrast, we successfully generated
cells that expressed a cytoplasmically truncated TbRII
(dnTbRII), which acts as a dominant negative inhibitor of
TGF-b signaling (Chen et al., 1993). Similar to what we
observed for wild-type TbRII, the expression of dnTbRII
was lower than the endogenous TbRII level. Whereas the
dnTbRII protein could not be convincingly detected in
metabolically labeled lysates (data not shown), it could be
detected in undifferentiated and differentiated dnTbRII
cells by cross-linking [125I]TGF-b to the cell-surface recep-
tors (Fig. 3, A and B). The low dnTbRII levels, when com-
pared with endogenous TbRII, suggested that the TGF-b
response in the dnTbRII cells would only be partially in-
hibited.
Using these cells, we evaluated the effect of dnTbRII ex-
pression on adipose differentiation, and in parallel, tested
the effect of TGF-b at 1 ng/ml, added 2 d before conflu-
ence and continuously present thereafter. At this dose,
TGF-b confers incomplete inhibition of adipose conver-
sion (Ignotz and Massagué, 1985; Choy, L., unpublished
data), which should enable us to detect the effects of en-
hancement or inhibition of TGF-b signaling. By 8 d after
confluence, the dnTbRII cells differentiated similarly to
the parental cells in the absence of added TGF-b, but were
partially resistant to the differentiation-inhibiting effect of
TGF-b, as judged by neutral lipid staining (Fig. 4 A).
Northern analysis of adipocyte differentiation markers
Figure 2. Northern analysis of Smad mRNA expression during
differentiation and in response to TGF-b treatment. Cells were
allowed to differentiate without added TGF-b, or in the presence
of 5 ng/ml TGF-b beginning at 2 d preconfluence, and RNA was
harvested at the days indicated. 10 mg total RNA was blotted and
sequentially hybridized to cDNA probes for Smad2, Smad3,
Smad4, Smad6, and Smad7, and for PPARg (as marker for adi-
pogenic conversion), as indicated. Ethidium bromide staining of
the gel (EtBr) is shown as a loading control. All autoradiograms
were exposed for 24 h except for PPARg, which was exposed
for 8 h.
Figure 3. Expression of cytoplasmically truncated dnTbRII in
stably infected preadipocytes (A) and adipocytes (B). Cell-sur-
face availability of TGF-b receptors was assessed by binding and
chemical cross-linking to [125I]TGF-b. The first two lanes of each
panel contain samples of total lysates, whereas the last two lanes
contain immunoprecipitations using anti-Flag antibody, which
recognizes the Flag epitope tag of dnTbRII. Positions of TbRII
(RII), TbRI (RI), and dnTbRII are indicated. Endogenous TbRI
coprecipitated with the dnTbRII, as expected. The mobility of
the receptors was slightly different in total lysates versus immu-
noprecipitates because of differing salt conditions and/or the
presence of IgG in the immunoprecipitates. Exposure times were
identical for all panels.
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was performed at various points during differentiation.
We analyzed the expression of the five transcription fac-
tors that are known to play important roles in adipogene-
sis (Grégoire et al., 1998), C/EBPb, C/EBPd, ADD-1,
PPARg, and C/EBPa, as well as the later markers aP2 and
adipsin. This study indicated that, while the extent of dif-
ferentiation of dnTbRII and control cells was similar at
day 8 after confluence, the rate of differentiation of dnTbRII
cells was enhanced when compared with the parental cells
(Fig. 4 B). Thus, at day 3 after confluence, the mRNA lev-
els for PPARg, C/EBPa, aP2, and adipsin were signifi-
cantly higher in dnTbRII cells than in control cells. In con-
trast, the mRNA levels of C/EBPb, C/EBPd, and ADD-1,
earlier markers of adipogenic differentiation, were similar
in both cell lines. The increased mRNA levels for PPARg,
C/EBPa, aP2, and adipsin in dnTbRII cells are consistent
with the ability of TGF-b to repress expression of these
markers (Torti et al., 1989; Stephens et al., 1993; Xing
et al., 1997) and suggest that endogenous TGF-b respon-
siveness regulates adipocyte differentiation. Accordingly,
TGF-b–treated control cells at day 8 after confluence ex-
hibited decreased expression of these four later markers,
as well as ADD-1, although they expressed C/EBPb and
C/EBPd at similar levels as untreated control cells. Consis-
tent with their impaired TGF-b responsiveness, TGF-
b–treated dnTbRII cells showed only slight inhibition of
the later differentiation markers.
TGF-b stimulates the proliferation of many types of
mesenchymal cells, including 3T3-F442A preadipocytes
(Jeoung et al., 1995). Therefore, we compared the growth
rates of control preadipocyte cells and dnTbRII cells, in
the absence or presence of added TGF-b. Growth was as-
sayed by [3H]thymidine incorporation, a measure of DNA
synthesis, under subconfluent conditions. In the absence
of added TGF-b, the growth rate of dnTbRII cells was
25–30% lower than that of the control cells, and in the
presence of TGF-b, the mitogenic response of dnTbRII
cells was only half of that of the control cells (Fig. 4 C).
These results show that, despite the modest dnTbRII ex-
pression level, the TGF-b response was significantly af-
fected. Collectively, these results show that the TGF-b re-
sponsiveness regulates adipocyte differentiation in culture,
and that impaired TGF-b responsiveness results in accel-
erated differentiation and slower growth.
Smad2 and Smad3 Differentially Regulate Adipogenesis 
and Cell Proliferation
To characterize the roles of Smad2 and Smad3 in adipo-
cyte differentiation of 3T3-F442A cells, we generated two
pairs of cell lines. One pair overexpressed wild-type
Smad2 or Smad3, while the complementary pair expressed
mutant versions of Smad2 (Smad2DSSMS) or Smad3
(Smad3DSSVS). These mutants lacked the last four amino
acids, including the COOH-terminal serines, and, thus,
cannot be phosphorylated by the activated TbRI. Simi-
larly to the 3SA derivatives of Smad2 and Smad3, in which
the last three serines are mutated to alanine (Macias-Silva
et al., 1996; Liu et al., 1997), overexpression of Smad2
DSSMS or Smad3DSSVS resulted in dominant negative in-
terference of signaling by Smad2 or Smad3 in transfection/
reporter assays (data not shown). Expression of wild-type
and mutant Smad2 or Smad3 proteins could be readily de-
tected in the stable cell populations (Fig. 5 A). While we
were unable to clearly detect endogenous Smad proteins,
the viral transcripts were expressed at a .100-fold higher
level than the endogenous Smad2 and Smad3 mRNAs
(data not shown).
We tested the abilities of these stable cell lines to un-
dergo adipocyte differentiation and the ability of TGF-b
to inhibit their differentiation. Expression of either Smad2
or Smad2DSSMS inhibited lipid accumulation, although
the effect of Smad2DSSMS was weaker than Smad2 (Fig. 5
B). Enhanced Smad3 expression resulted in a stronger in-
hibitory effect than Smad2 overexpression, while cells ex-
pressing Smad3DSSVS differentiated similarly to vector
control cells (Fig. 5 B). In the presence of 1 ng/ml TGF-b,
Smad2 or Smad3 expression both significantly augmented
Figure 4. Effects of expression of dnTbRII on adipogenesis and
cell proliferation. (A) Adipogenesis of control (vector) and
dnTbRII cells was assessed by the extent of lipid accumulation,
visualized by Oil Red O staining after 8 d in differentiation me-
dium, either without or with 1 ng/ml TGF-b. (B) Northern analy-
sis of adipocyte marker mRNA expression. Vector control or
dnTbRII cells, grown in differentiation medium without or with
1 ng/ml TGF-b, as indicated, were harvested at the indicated days
after confluence. 10 mg total RNA was blotted and sequentially
hybridized to the cDNA probes as shown. Ethidium bromide
staining of the gel (EtBr) is shown to illustrate the similar RNA
loading of the lanes. (C) Proliferation rate of vector control and
dnTbRII cells, as assessed by the incorporation of [3H]thymidine,
either without treatment or in response to 5 ng/ml TGF-b. Values
are expressed as fold induction relative to the untreated vector
control.
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the differentiation-inhibiting effect of TGF-b (Fig. 5 C).
However, the effect of Smad3 was stronger than Smad2;
no lipid-accumulating cells were found in the Smad3-
expressing cultures, whereas a few could be seen among
the cells overexpressing Smad2. Cells expressing Smad3
DSSVS differentiated to a much greater extent than con-
trol cells in the presence of TGF-b, demonstrating that this
Smad3 mutant blocked the differentiation-inhibitory ef-
Figure 5. Effect of Smad2, Smad3, or their dominant negative
mutants on adipogenesis. (A) Expression of Flag-tagged Smads
in their respective stable cell lines. Whole cell lysates were immu-
noprecipitated using anti-Flag–conjugated beads, followed by
Western blotting with anti-Flag antibody. Position of background
IgG is indicated. (B and C) The effect of overexpression of
Smad2, Smad3, or their dominant negative mutants on lipid accu-
mulation in adipogenic differentiation. Untreated cells (B) and
cells treated with 1 ng/ml (C) at 8 d after confluence are shown.
Figure 6. Effect of Smad2, Smad3, or their dominant negative
mutants on differentiation-dependent gene expression and pro-
liferation in the absence and presence of TGF-b. (top) Northern
analysis of adipocyte marker gene expression. Total RNA from
stable cell lines was isolated on the indicated days and processed
as in Fig. 4 B. 2TGF-b lanes: Smad2D, Smad2DSSVS, Smad3D,
and Smad3DSSVS. All RNA samples of cells without TGF-b
treatment were on the same membrane, but the autoradiogram in
the figure has been cut into panels for easier viewing. 1TGF-b
lanes: v, vector; 2, Smad2; 2D, Smad2DSSMS; 3, Smad3; and 3D,
Smad3DSSVS. (bottom) Proliferation rate of vector control
cells and cells overexpressing Smad2, Smad3, Smad2DSSMS, or
Smad3DSSVS are as shown. Cells were either untreated or
treated with 5 ng/ml TGF-b, and the level of [3H]thymidine in-
corporation was measured. Values are expressed as fold induc-
tion relative to the untreated vector control.
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fect of TGF-b. In contrast, expression of Smad2DSSMS
did not block this effect of TGF-b, and slightly enhanced
the inhibitory effect of TGF-b (Fig. 5 C).
The effect of these Smads on lipid accumulation was re-
flected in the expression pattern of adipocyte differentia-
tion mRNAs (Fig. 6 A). The induction of PPARg, ADD-1,
C/EBPa, aP2, and adipsin was strongly reduced in cells
with increased Smad3 expression, whereas the differentia-
tion-dependent suppression of C/EBPd was abrogated.
Smad2 or Smad2DSSMS expression resulted in only a
slight decrease in the differentiation-dependent induction
of the differentiation markers, whereas Smad3DSSVS ex-
pression did not significantly alter their expression. In the
presence of TGF-b, the Smad3DSSVS cells expressed
PPARg, C/EBPa, aP2, and adipsin at higher levels than in
TGF-b–treated control cells, suggesting that impaired
Smad3 signaling suppresses the responsiveness to TGF-b.
In contrast, Smad2DSSMS expression enhanced the TGF-
b–mediated suppression of these differentiation markers,
although to a lesser extent than in cells overexpressing
Smad2 or Smad3.
We also measured the effect of overexpression of Smad2
or Smad3 or their dominant negative mutants on the
growth rate (Fig. 6 B). Expression of Smad2 or Smad2
DSSMS had little if any effect on cell proliferation or its
stimulation by TGF-b. In contrast, Smad3 overexpression
stimulated cell growth about threefold, both in the pres-
ence or absence of TGF-b. Expression of Smad3DSSVS
inhibited the growth rate in the presence of TGF-b, and
was z30% less than the vector alone (Fig. 6 B).
Finally, we evaluated the effect of TGF-b on the mor-
phology of these cell lines (Fig. 7). Adipogenic conversion
Figure 7. Morphology of
cells overexpressing Smad2
or Smad3 or their dominant
negative mutants. Except for
A, all cells were treated with
1 ng/ml TGF-b. (A) Vector
control cells, untreated; (B)
vector control cells; (C)
Smad2-expressing cells; (D)
Smad3 expressing cells;
(E) Smad2DSSMS-express-
ing cells; and (F) Smad3
DSSVS-expressing cells.
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of control cells in the absence of TGF-b resulted in round-
ing, accumulation of lipid droplets, and a consequent en-
largement of the cells, whereas nearby cells that had not
yet undergone differentiation maintained a fibroblastic
appearance (Fig. 7 A). TGF-b treatment prevented cell
rounding and lipid accumulation and conferred a more
densely packed, spindly morphology to the cells (Fig. 7 B).
Increased expression of Smad2 (Fig. 7 C) or Smad3 (Fig. 7
D) enhanced these typical TGF-b–induced morphological
changes; however, the effect of Smad3 was stronger than
that of Smad2, which is consistent with the milder effects
of Smad2 versus Smad3 on TGF-b–induced inhibition of
lipid accumulation (Fig. 5 C). Expression of Smad2DSSMS
conferred a morphology intermediate between the vector
control and Smad2 overexpressing cells (Fig. 7 E). In con-
trast, Smad3DSSVS expression counteracted the cell shape
changes induced by TGF-b and allowed a level of lipid ac-
cumulation (Fig. 7 F), which approached that of control
cells in the absence of TGF-b (Fig. 7 A). In the absence of
TGF-b, the morphology of the different Smad-expressing
cell lines was similar to each other, except that the Smad3-
expressing cells were somewhat more spindly and densely
packed (data not shown), which is consistent with a consti-
tutive level of TGF-b signaling. These results identify
Smad3 as a major regulator of adipogenic differentiation
and of TGF-b–mediated inhibition of adipogenic conver-
sion and growth stimulation. The Smad2 effects appear to
be more complex and may reflect its involvement in only
some TGF-b effects, yet suggest that Smad2 is also an im-
portant regulator of normal adipocyte differentiation.
Overexpression of Smad6 or Smad7 Blocks 
Adipogenesis and Enhances TGF-b–induced Growth 
and Inhibition of Differentiation
In contrast to the roles of Smad2 and Smad3 as TGF-b sig-
naling effectors, Smad6 and Smad7 inhibit signaling by
TGF-b family members. We hypothesized that the overex-
Figure 8. Generation and differentiation of Smad6 or Smad7
overexpressing cell lines. (A) Whole cell lysates of vector control,
Smad6, or Smad7 expressing cells were analyzed by anti-Flag im-
munoprecipitation and anti-Flag Western blotting. (B) Lipid ac-
cumulation in Smad6 and Smad7 overexpressing cell lines. Vec-
tor control and Smad6 or Smad7-overexpressing cell lines were
grown under differentiation conditions in the absence or pres-
ence of 1 ng/ml TGF-b. At 8 d after confluence, the cells were
fixed and stained with Oil Red O.
Figure 9. Analysis of differentiation marker expression and pro-
liferation in Smad6- and Smad7-overexpressing cells. (top)
Northern analysis of adipocyte marker gene expression. Total
RNA was isolated on the indicated days from vector control and
Smad6- or Smad7-expressing cells and processed as in Fig. 4 B.
All RNA samples were on the same membrane, but the autora-
diogram in the figure has been cut into panels for easier viewing.
(bottom) Cell proliferation in the absence or presence of TGF-b.
TGF-b was added to 5 ng/ml, and [3H]thymidine incorporation
was measured. Values are expressed as fold induction relative to
the untreated vector control.
Choy et al. TGF-b and Smads in Adipocyte Differentiation 675
pression of these proteins might result in a more complete
blockade of TGF-b signaling than expression of domi-
nant negative Smad2 or 3 mutants expressed alone, or of
dnTbRII. Furthermore, the downregulation of both Smad6
and Smad7 during adipocyte differentiation (Fig. 2) sug-
gested a function for these Smads in the differentiation
process. Therefore, we evaluated the consequences of sta-
ble overexpression of these two inhibitory Smads. Retrovi-
ral expression of Smad6 exceeded by far the expression
level of Smad7 (Fig. 8 A). Expression of the viral mRNAs
for these Smads was much higher than the corresponding
endogenous Smad transcripts (data not shown).
These cells were cultured under differentiation condi-
tions, in the presence or absence of TGF-b, to assess the
effects of Smad6 or Smad7 on adipogenic conversion, and
on the ability of TGF-b to block differentiation. Expres-
sion of either Smad protein resulted in a profound block-
age of lipid accumulation (Fig. 8 B). Despite its lower
expression level (Fig. 8 A), the differentiation blockage in-
duced by Smad7 was greater than that induced by Smad6.
In the presence of TGF-b, this inhibition was even more
complete, and no adipocytes could be found in Smad7
overexpressing cell cultures treated with TGF-b. These ef-
fects of Smad6 and Smad7 on adipose conversion were
Figure 10. Morphology of
vector control cells versus
Smad6- and Smad7-overex-
pressing cells. (A) Cells dur-
ing active growth phase. (B)
4 d after confluence in differ-
entiation medium. [Arrow-
head in Smad6 panel in-
dicates cluster of small
adipocytes.] (C) 4 d after
confluence in differentiation
medium with 1 ng/ml TGF-b.
(D) Same as B except that an
example of giant Smad7 cells
is shown.
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also apparent in the analysis of adipocyte marker expres-
sion (Fig. 9 A). While C/EBPb levels were not strongly af-
fected, Smad6 or Smad7 overexpression increased the lev-
els of C/EBPd, which is normally downregulated during
differentiation. These cells also showed strongly reduced
PPARg, C/EBPa, aP2, and adipsin mRNAs, and a moder-
ately reduced ADD-1 mRNA level. In the presence of
TGF-b, all the TGF-b–induced changes in mRNA ex-
pression were enhanced by overexpression of Smad6 or
Smad7.
We next tested the effect of Smad6 or Smad7 overex-
pression on cell proliferation in the absence or presence of
TGF-b. Smad6 or Smad7 overexpression both greatly po-
tentiated TGF-b–induced growth stimulation (Fig. 9 B) to
a similar magnitude as Smad3 overexpression (Fig. 6 B).
However, in contrast to the effect of Smad3 overexpres-
sion, the basal growth rate in the absence of added TGF-b
was unchanged. Therefore, we conclude that Smad6 or
Smad7 expression cooperates with TGF-b to enhance cell
proliferation, but not in the same manner as Smad3.
The Smad6- or Smad7-expressing cells had an unusual
morphology. When subconfluent, the cells were overall
similar in size, but the Smad6 and Smad7 cells had a more
cuboidal appearance and smoother edges, and seemed
more contact-inhibited than control cells (Fig. 10 A). Af-
ter reaching confluence under conditions that normally re-
sult in adipocyte differentiation, Smad6 and especially
Smad7-overexpressing cells became very large and flat, in
contrast to the compact piles of rounded, lipid-filled cells
in control cultures (Fig. 10 B). The Smad7-overexpressing
cells were generally larger and flatter than the Smad6-
expressing cells, and had a higher incidence of giant cells,
which were about fivefold larger than the surrounding
cells (Fig. 10 D). The few adipocytes that did appear in the
Smad6 or Smad7 cell cultures were very small in compari-
son to control adipocytes, and did not accumulate much
lipid (Fig. 10 B, arrow). In the presence of TGF-b, all cell
lines had a similar morphology, with the exception of the
Smad6 or Smad7 cell cultures, which contained a few of
the remnant larger cells (Fig. 10 C), and appeared larger
overall.
To identify the domain of Smad7 that is required for its
effects on adipogenesis, we evaluated the effects of expres-
sion of two different Smad7 mutants. The Smad7DC mu-
tant has a 19–amino acid deletion at the COOH terminus,
a mutation which abrogates the ability of Smad7 to block
TGF-b receptor signaling (Hayashi et al., 1997). Con-
versely, expression of only the C-domain of Smad7, i.e.,
the Smad7C protein, is sufficient to block TGF-b receptor
signaling similarly to full-length Smad7 (Souchelnytskyi et
al., 1998). We stably expressed these mutant Smad7 pro-
teins in 3T3-F442A cells, at levels similar to wild-type
Smad7 (Fig. 11 A). The Smad7DC expressing cells accu-
mulated lipid similarly as the vector control cells, whereas
lipid accumulation was blocked in the Smad7C expressing
cells (Fig. 11 B). Differentiation, as assessed by expression
of PPARg mRNA, also indicated that Smad7C, but not
Smad7DC, decreased differentiation (Fig. 11 C). Stain-
ing and PPARg mRNA expression also revealed that
Smad7C, but not Smad7DC, cooperated with TGF-b in
blocking differentiation (Fig. 11, B and C). Smad7C, but
not Smad7DC, also synergized with TGF-b in stimulating
DNA synthesis (Fig. 11 D). Finally, the phenotype of the
Smad7C cells resembled that of cells expressing wild-type
Smad7, whereas Smad7DC-expressing cells resembled vec-
tor control cells (Fig. 11 E). While Smad7C was qualita-
tively identical to wild-type Smad7 in our assays, it was
quantitatively a weaker effector in comparison to full-
length Smad7. 
Our results indicate that Smad6 and Smad7 enhance,
rather than inhibit, the effects of TGF-b signaling on
adipogenic differentiation and cell proliferation. The
C-domain of Smad7, which has been shown to be required
for inhibition of TGF-b signaling in other experimental
systems, is necessary and sufficient for its effects on adipo-
cytic differentiation in 3T3-F442A cells.
Discussion
The ability of TGF-b and TGF-b–related factors to reg-
ulate mesenchymal differentiation is well documented.
Nevertheless, little is known about the role of endogenous
signaling by TGF-b, or its related factors, or the Smads, in
cell differentiation. In this study, we have investigated the
Figure 11 (continues on facing page).
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functions of endogenous TGF-b and Smad signaling in ad-
ipocyte differentiation, using a well-known model system
for adipocyte differentiation. While exogenous TGF-b is
known to inhibit adipocyte differentiation, TGF-b also has
been shown to be endogenously produced by adipocytes.
Furthermore, preadipocytes secrete and activate TGF-b,
whereas mature adipocytes do not (Rahimi et al., 1998).
These observations suggested a role for autocrine TGF-b
signaling in adipocyte differentiation. We now show that
endogenous TGF-b receptor signaling is regulated dur-
ing adipocyte differentiation, that autocrine TGF-b sig-
naling modulates differentiation, and that Smad2 and
Smad3 have distinct roles in the differentiation of these
cells. Finally, our results indicate that Smad6 and Smad7
act as negative regulators of adipocyte differentiation,
and enhance, rather than inhibit, TGF-b signaling in
these cells.
Regulation and the Role of TGF-b Receptor Signaling 
in Adipogenesis
To characterize the potential role of autocrine TGF-b in
adipose differentiation, we assessed the availability of re-
ceptors for TGF-b binding during differentiation. We
found that the cell-surface expression of the TGF-b recep-
tors is strongly downregulated during adipose differentia-
tion. Our results are in accordance with the strong de-
crease in ligand binding during differentiation of primary
rat adipocytes (Serrero and Mills, 1991) and of HIB-1B
brown adipocytes (data not shown), but contrast with the
apparent lack of repression of TGF-b binding in differen-
tiating 3T3-L1 preadipocytes (Ignotz and Massagué, 1985;
data not shown). Since TGF-b inhibits adipocyte differen-
tiation, the repression of TGF-b receptor availability may
enable the cells to withdraw from the autocrine, differenti-
ation inhibitory activity of TGF-b. This downregulation
Figure 11. Effect of expres-
sion of Smad7DC versus
Smad7C on differentiation,
proliferation, and cell mor-
phology. (A) Expression of
Smad7C and Smad7DC in
stable 3T3-F442A cell lines,
as determined by Flag immu-
noprecipitation and Western
blotting. The expression of
wild-type Smad7 in the cor-
responding stable 373-F442A
cell line is shown alongside to
enable a comparison of the
expression levels. (B) Lipid
accumulation in Smad 7DC-
and Smad7C-expressing cells.
Vector control and Smad7DC-
or Smad7C-expressing cell
lines were grown as in Fig. 8
B, and stained with Oil Red
O. (C) Northern analysis
of PPARg expression in
Smad7DC- and Smad7C-
expressing cells. Total RNA
was isolated on the days indi-
cated, blotted, and hybrid-
ized as in Fig. 4 B. (D) Cell
proliferation in the absence
or presence of TGF-b. Cells
were untreated, or TGF-b
was added to 5 ng/ml, and
[3H]thymidine incorporation
was measured. Values are
expressed as fold induction
relative to the untreated vec-
tor control. (E) Cell mor-
phology of Smad7DC- and
Smad7C-expressing cells at
4 d after confluence in differ-
entiation medium without
(top row) or with (bottom
row) 1 ng/ml TGF-b.
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may also explain why cells become refractory to the differ-
entiation-inhibitory effect of TGF-b once differentiation
has commenced. Accordingly, TGF-b did not inhibit 3T3-
F442A adipose conversion at 3–4 d after confluence, by
which time there is a significant loss of TGF-b binding
(data not shown).
The downregulation of cell-surface TGF-b receptors in
3T3-F442A adipocytes is reminiscent of observations in
other types of mesenchymal differentiation. Differentia-
tion of myoblasts into myocytes is accompanied by a
strong decrease in TGF-b binding sites at the cell surface
(Hu and Olson, 1990), whereas the availability of type II
but not type I TGF-b receptors is downregulated during
osteoblastic differentiation (Centrella et al., 1995). These
observations suggest that autocrine TGF-b signaling con-
trols mesenchymal cell differentiation, and that these cells
alter their autocrine TGF-b response during differentia-
tion to allow for efficient maturation. Other mechanisms
in addition to receptor availability may also be involved;
e.g., 3T3-L1 adipocytes differentiate without repressing
TGF-b binding (Ignotz and Massagué, 1985), but differen-
tiation is accompanied by a block in activation of auto-
crine latent TGF-b (Rahimi et al., 1998).
The differentiation-inhibiting role of autocrine TGF-b
in adipogenesis was confirmed in cells expressing a domi-
nant negative version of the type II TGF-b receptor. Even
though we did not obtain high levels of dnTbRII expres-
sion, the cells showed a decreased response to TGF-b. The
dnTbRII cells had accelerated differentiation, suggesting
that autocrine TGF-b responsiveness regulates adipose
conversion. These observations suggest that decreased
receptor availability during adipogenesis allows these
cells to escape the autocrine differentiation-inhibitory and
growth-promoting roles of TGF-b. The observation that
retrovirally expressed cell-surface wild-type or dnTbRII
were not decreased during differentiation, whereas endog-
enous cell-surface TbRII was decreased without a de-
crease in mRNA levels, suggests that the differentiation-
dependent decrease in receptor availability results from
translational repression.
Regulation and the Roles of Smad2 and Smad3
in Adipogenesis
Smad2 and Smad3 are both activated in response to TGF-b
and act, in cooperation with Smad4, as effectors of the
TGF-b response. All three Smads are expressed in 3T3-
F442A cells, and their mRNA levels do not change signifi-
cantly during differentiation. Whether Smad protein levels
or their activation are altered during differentiation is cur-
rently unknown and awaits the availability of better anti-
bodies. Our data also show that TGF-b represses Smad3
but not Smad2 mRNA expression, and that this TGF-
b–induced repression decreases with differentiation, which
is consistent with the downregulation of the cell-surface
TGF-b receptors. Whether cells alter Smad expression
and activation as a mechanism to regulate TGF-b respon-
siveness during differentiation is currently unclear. How-
ever, a recent report suggests differential expression of
Smads at different stages during maturation of chondro-
cytes (Sakou et al., 1999).
To characterize the roles of Smad2 and Smad3, we gen-
erated 3T3-F442A cells that stably overexpress either
wild-type or dominant negative versions of Smad2 or
Smad3. We assessed the effect of these manipulations on
preadipocyte growth and differentiation, and the TGF-b
response. This study revealed different roles for Smad2
and Smad3. Overexpression of Smad3 decreased differen-
tiation and increased proliferation in the absence or pres-
ence of TGF-b, suggesting that Smad3 overexpression
mimicked and enhanced the TGF-b response. Conversely,
dominant negative interference with Smad3 signaling en-
hanced the rate and extent of differentiation and inhibited
cell proliferation. These results suggest that Smad3 medi-
ates the differentiation-inhibiting and proliferative re-
sponses to TGF-b.
In contrast to Smad3, alterations of Smad2 function did
not affect cell proliferation, in the absence or presence of
TGF-b. However, increased Smad2 levels inhibited differ-
entiation, albeit to a milder extent than Smad3, and en-
hanced the differentiation inhibitory response to TGF-b.
Remarkably, expression of dominant negative Smad2 had
a similar, but smaller, effect on differentiation as wild-type
Smad2. These observations were not peculiar to the
DSSXS mutations, since cells stably expressing dominant
negative versions of Smad2 or Smad3 with the last three
serines mutated to alanines (Macias-Silva et al., 1996; Liu
et al., 1997), behaved identically to the DSSXS mutants
(data not shown). In principle, this effect could be ex-
plained by a possible weak residual activity of the mutated
Smad2DSSMS or Smad2SA; however, this seems unlikely
since we did not observe such behavior with the corre-
sponding mutants of Smad3. Since Smad2 is also activated
by activin, dominant negative interference with Smad2 sig-
naling may primarily inhibit activin signaling, and this
effect could explain the ability of Smad2DSSMS to in-
hibit differentiation and to enhance the TGF-b response.
Whether activin signaling contributes to adipogenesis re-
mains to be explored since nothing is yet known about the
function of activin in adipocyte differentiation.
Regulation and the Roles of Smad6 and Smad7
in Adipogenesis
While Smad2 and Smad3 are effectors of the TGF-b re-
sponse, Smad6 and Smad7 have been shown to act as in-
hibitors of TGF-b responses. In contrast to Smad2 and
Smad3, Smad6 and Smad7 mRNA expression is strongly
repressed as adipogenesis proceeds. Since TGF-b can in-
duce Smad6 and Smad7 expression (Nakao et al., 1997;
Afrakhte et al., 1998; Chen et al., 1999), it is possible that
the loss of Smad6 and Smad7 expression results from the
downregulation of cell-surface receptors for TGF-b and,
consequently, a lack of autocrine TGF-b stimulation.
The downregulation of Smad6 and Smad7 suggested
that these Smads normally exert an inhibitory effect on ad-
ipocyte differentiation, which is suppressed by the cells to
allow full differentiation. Alternatively, the inhibitory ef-
fect of Smad6 and Smad7 on the TGF-b response could
suggest that increased Smad6 or Smad7 expression would
favor adipogenic differentiation. Remarkably, Smad6 or
Smad7 overexpression blocked adipogenesis and enhanced
the inhibitory effect of TGF-b on differentiation. In addi-
tion, Smad6 or Smad7 overexpression also enhanced the
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TGF-b–induced stimulation of cell proliferation, without
changing the growth rate in the absence of exogenous
TGF-b. This effect contrasts with the growth stimulatory
effect of Smad3 overexpression, which enhances cell pro-
liferation both in the absence or presence of TGF-b. While
the activities of Smad6 and Smad7 appeared qualitatively
the same, Smad7 was more potent than Smad6, in spite of
its lower level of overexpression.
The mechanisms by which Smad6 and Smad7 block adi-
pocyte differentiation and enhance the TGF-b response
are unclear. However, we determined that the C-domain
of Smad7 is necessary and sufficient for these effects in
3T3-F442A cells. This region is also required for the inhib-
itory effect of Smad7 on TGF-b receptor signaling (Ha-
yashi et al., 1997; Souchelnytskyi et al., 1998), suggesting
that the mechanism could be receptor-mediated. Since the
inhibitory effects of Smad6 and Smad7 on ligand-induced
responses are not restricted to TGF-b, it is conceivable
that the observed phenotype results from inhibition of au-
tocrine responsiveness to another TGF-b family member,
such as BMP or activin. Accordingly, BMPs have been
shown to regulate adipogenic differentiation: BMP-7 stim-
ulates (Asahina et al., 1996) whereas BMP-2 has been re-
ported to stimulate or inhibit adipogenic differentiation
(Ahrens et al., 1993; Wang et al., 1993; Gimble et al.,
1995). The differentiation stage and relative expression of
the two BMP type I receptors, BMP-RIA and -RIB, may
determine the nature of the autocrine response. Interfer-
ence with BMP-RIA signaling can inhibit adipocyte con-
version of mouse calvarial 2T3 cells, whereas a block in
BMP-RIB signaling promotes adipocyte differentiation of
these cells (Chen et al., 1998). Whether the differentiation
and proliferation phenotypes of our Smad6 or Smad7
overexpressing cells can be explained through inhibition
of BMP signaling remains to be investigated.
The molecular basis for the remarkable phenotype of
the large cells in the Smad6 or Smad7 overexpressing cell
lines also remains to be determined. It is conceivable that
this phenotype results from an indiscriminate block in au-
tocrine responsiveness to the different TGF-b–related fac-
tors by Smad6 or Smad7. This blockage may disable the
mesenchymal differentiation program, which would be
consistent with the ability of Smad7 to block mesoderm
differentiation and to induce formation of neural tissue in
Xenopus (Bhushan et al., 1998; Casellas and Hemmati-
Brivanlou, 1998). Similar data have been presented for
Smad6 (Nakayama et al., 1998). However, the phenotype
of our Smad6 and Smad7 stable cell lines does not suggest
acquisition of a neuronal phenotype, and indeed, devel-
opment of neural tissue in Xenopus is believed to be a
default developmental response. Thus, Smad6 or 7 overex-
pression may prevent differentiation along the mesen-
chymal lineage.
In summary, our results suggest that autocrine TGF-b
regulates the rate of adipose conversion, and that cells re-
duce their autocrine response to TGF-b by repressing the
availability of the TGF-b receptors as they differentiate.
The effects of TGF-b on preadipocyte differentiation are
mediated by Smad2 and Smad3, which have distinct func-
tions in differentiation. The mechanisms by which Smad2
and Smad3 block differentiation may be related to their
well-known ability to interact with and modify the activity
of transcription factors. Whether these Smads target the
transcription factors that drive adipose differentiation is
currently under investigation. Since TGF-b did not affect
the induction of C/EBPb and -d, but blocked the induction
of ADD-1, PPARg, and C/EBPa, Smad2 or Smad3 may
exert their effects at some point upstream of ADD-1 and
PPARg induction. The function of Smad6 and Smad7 may
be to block premature differentiation (akin to the function
of autocrine TGF-b production), possibly by blocking sev-
eral TGF-b family signaling pathways. The current obser-
vations provide a basis for the investigation of the molecu-
lar mechanisms whereby these Smads regulate adipocyte
differentiation.
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